Ftse Mib
33.766,29
-0,06%
DAX
19.884,75
-0,57%
S&P 500
5.930,85
1,09%
NASDAQ
19.572,60
1,03%
Bitcoin
96.881,41
-0,33%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Revance Therapeutics Inc (RVNC) Revance Therapeutics Inc (RVNC) Notizie

Revance Therapeutics Inc

RVNC
3,05
-0,03 (-0,97%)
20 Dic 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
19/12/202415:00EDGAR2Form SCHEDULE 13D/A - General Statement of Acquisition of..
12/12/202414:01EDGAR2Form SC 14D9 - Solicitation, recommendation statements
12/12/202414:00PRNUSCrown Laboratories Commences Friendly Tender Offer for All..
12/12/202413:15EDGAR2Form SC TO-T - Tender offer statement by Third Party
12/12/202412:01EDGAR2Form 8-K - Current report
09/12/202423:16EDGAR2Form SC TO-C - Written communication relating to an issuer..
09/12/202415:24EDGAR2Form SC14D9C - Written communication relating to third party..
09/12/202415:17EDGAR2Form 8-K - Current report
09/12/202414:30PRNUSCrown Laboratories and Revance Enter into Amended and..
05/12/202422:23EDGAR2Form 8-K - Current report
03/12/202414:27EDGAR2Form 8-K - Current report
29/11/202412:02EDGAR2Form 8-K - Current report
26/11/202412:01EDGAR2Form 8-K - Current report
19/11/202422:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/11/202422:01EDGAR2Form 8-K - Current report
07/11/202422:12EDGAR2Form 8-K - Current report
07/11/202422:05BWRevance Reports Third Quarter 2024 Financial Results,..
01/11/202414:24EDGAR2Form 8-K - Current report
18/10/202415:29EDGAR2Form 8-K - Current report
04/10/202413:32EDGAR2Form 8-K - Current report
27/9/202415:17PRNUSKuehn Law Encourages RVNC, RFL, BTTR, and ARC Investors to..
23/9/202413:15EDGAR2Form 8-K - Current report
16/9/202423:01EDGAR2Form SC 13G - Statement of Beneficial Ownership by Certain..
09/9/202422:06EDGAR2Form 8-K - Current report
05/9/202423:27EDGAR2Form SC14D9C - Written communication relating to third party..
05/9/202422:45EDGAR2Form SC TO-C - Written communication relating to an issuer..
13/8/202415:29EDGAR2Form SC TO-C - Written communication relating to an issuer..
12/8/202423:18EDGAR2Form SC14D9C - Written communication relating to third party..
12/8/202421:18PRNUSALERT: Rowley Law PLLC is Investigating Proposed Acquisition..
12/8/202415:20EDGAR2Form 8-K - Current report
12/8/202414:00PRNUSCrown Laboratories and Revance Announce Entry Into Merger..
09/8/202415:00EDGAR2Form 8-K - Current report
08/8/202422:34EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202422:07EDGAR2Form 8-K - Current report
08/8/202422:05BWRevance Reports Second Quarter 2024 Financial Results,..
01/8/202422:05BWRevance to Release Second Quarter 2024 Financial Results on..
14/6/202422:05BWRevance Reports Inducement Grants Under Nasdaq Listing Rule..
28/5/202422:05BWRevance to Participate in Upcoming Investor Conferences
09/5/202422:33EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/5/202422:08EDGAR2Form 8-K - Current report
09/5/202422:06BWRevance Reports First Quarter 2024 Financial Results,..
09/5/202422:05BWRevance Expands into the U.S. Therapeutics Market with the..
02/5/202422:05BWRevance to Release First Quarter 2024 Financial Results on..
12/4/202414:00BWRevance to Present New DAXXIFY® Data at the American Academy..
27/3/202421:05BWRevance Reports Inducement Grants Under Nasdaq Listing Rule..
08/3/202422:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202423:08EDGAR2Form 8-K - Current report
05/3/202423:00EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
04/3/202423:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202423:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
Apertura: 3,07 Min: 3,07 Max: 3,09
Chiusura: 3,08

La tua Cronologia

NASDAQ
RVNC
Revance Therapeutics
AMEX
PIP
BIT
I10418
IT0005615619 20250620 26...
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network